Вы искали: kehapindala (Эстонский - Английский)

kehapindala
950 mg/ m2

kehapindala (m2)
body surface area (m2 )

kehapindala* (m2)
body surface area* (m²)

kehapindala vahemik (m2)
body surface area (bsa) range (m2)

bsa= kehapindala (body surface area)
bsa = body surface area

annus arvutatakse patsiendi kehapindala kohta ravi alguses.
the dose is calculated using the patient’s baseline body surface area (bsa).

0,05 mg/ml bsa= kehapindala (body surface area)
0.05 mg/ml bsa = body surface area

abraxane soovitatav annus on 100 mg kehapindala ruutmeetri kohta.
the recommended dose of abraxane is 100 mg per square metre of body surface area.

ei ole selge, kas see on seotud soo või kehapindala suurusega.
it is unclear whether this is a gender or a body size effect.

* kehapindala on võimalik välja arvutada järgneva valemi alusel:
* body surface area can be calculated with the following equation

kehapindala (bsa) arvutamiseks on soovitatav kasutada mostelleri valemit:
to calculate bsa, it is recommended to use mosteller’s equation:

lastel tuleb annustamise aluseks võtta kehapindala (mg/m2).
dosing for children should be on the basis of body surface area (mg/m2).

ravimi annus arvutatakse teie pikkuse ja kehakaalu (kehapindala) põhjal.
the dose will be calculated based on your height and weight (body surface area).

kehapindala (bsa) arvutada 2 kümnendkoha täpsusega. a väljendatuna tegafuuri sisaldusena.
calculate bsa to 2 decimal places. a expressed as tegafur content.

cellcept kapsleid tohib määrata ainult neile, kelle kehapindala on vähemalt 1,25 m2.
cellcept capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.

myclauseni kapsleid tohib määrata ainult neile, kelle kehapindala on suurem kui 1,25 m2.
myclausen capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.

myfenax kapsleid tohib määrata ainult neile patsientidele, kelle kehapindala on vähemalt 1,25 m2.
myfenax capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.

annustamisjuhised lastel soovitatav 100/ 25 mg tablettide arv kehapindala (m2) annustamiseks 2 korda ööpäevas
in rats, embryofoetotoxicity (pregnancy loss, decreased foetal viability, decreased foetal body weights, increased frequency of skeletal variations) and postnatal developmental toxicity (decreased survival of pups) was observed at maternally toxic dosages.

soovitatav annus on 260 mg kehapindala ruutmeetri kohta (arvutatakse patsiendi pikkuse ja kehamassi järgi).
the recommended dose is 260 mg per square metre of body surface area (calculated using the patient’s height and weight).

sarnaselt oli aktiivse metaboliidi kliirensi oluline ühismuutuja kehapindala (mida väiksem kehapindala, seda aeglasem kliirens).
similarly, body surface area was a significant covariate on the apparent clearance of the active metabolite (the lower the body surface area, the lower the apparent clearance).